Last reviewed · How we verify
HRQoL During PRRT in Patients With NETs
Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which may affect the patients' health-related quality of life (HRQoL). Up to four cycles of peptide receptor radionuclide therapy (PRRT) have been shown effective for symptom alleviation and prolonging survival. The aim of this study is to assess the patient's perspective, regarding changes in their HRQoL during, and at long-term follow-up after, PRRT. Patients with NET will rate their HRQoL before PRRT cycles one and four, and 1-8 years after PRRT. The patients' HRQoL will be compared to a matched reference population. The investigators hope that this study will reveal specific care needs for patients wiht NET and may provide information that will make it possible to deliver a more person-centered care.
Details
| Lead sponsor | Uppsala University |
|---|---|
| Status | COMPLETED |
| Enrolment | 756 |
| Start date | Sat Jan 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Dec 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Neuroendocrine Tumors
- Quality of Life
- Peptide Receptor Radionuclide Therapy